Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Amortizatization of Intangibles: 2019-2025

Historic Amortizatization of Intangibles for IDEAYA Biosciences (IDYA) over the last 7 years, with Sep 2025 value amounting to $2.0 million.

  • IDEAYA Biosciences' Amortizatization of Intangibles fell 63.04% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year decrease of 39.76%. This contributed to the annual value of $23.2 million for FY2024, which is 101.10% up from last year.
  • As of Q3 2025, IDEAYA Biosciences' Amortizatization of Intangibles stood at $2.0 million, which was down 26.37% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, IDEAYA Biosciences' Amortizatization of Intangibles ranged from a high of $6.6 million in Q2 2024 and a low of -$469,000 during Q4 2021.
  • For the 3-year period, IDEAYA Biosciences' Amortizatization of Intangibles averaged around $3.9 million, with its median value being $3.8 million (2025).
  • Per our database at Business Quant, IDEAYA Biosciences' Amortizatization of Intangibles slumped by 8,980.00% in 2021 and then surged by 964.84% in 2023.
  • Quarterly analysis of 5 years shows IDEAYA Biosciences' Amortizatization of Intangibles stood at -$469,000 in 2021, then soared by 177.61% to $364,000 in 2022, then surged by 964.84% to $3.9 million in 2023, then rose by 26.83% to $4.9 million in 2024, then slumped by 63.04% to $2.0 million in 2025.
  • Its Amortizatization of Intangibles was $2.0 million in Q3 2025, compared to $2.7 million in Q2 2025 and $3.8 million in Q1 2025.